Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976982 | 0.97 | HRH3 (1.00) | HRH3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2971446 | 0.89 | HRH3 (1.00) | HRH3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2969539 | 0.88 | HRH3 (0.84) | HRH3KCNH2 | |
| SCHEMBL2965073 | 0.88 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL524373 | 0.88 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL2960353 | 0.87 | HRH3 (0.80) | HRH3KCNH2 | |
| SCHEMBL2913592 | 0.86 | HRH3 (0.76) | HRH3KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2976226 | 0.86 | HRH3 (1.00) | HRH3KCNH2SLC6A4 | |
| SCHEMBL2975486 | 0.86 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL524421 | 0.86 | HRH3 (0.80) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032536-B1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | claimed |
| US-20150087635-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | claimed |
| US-8637520-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-28 | — | — | US | claimed |
| US-20100267701-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | US | claimed |
| EP-2032536-A2 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-11 | — | — | EP | claimed |
| WO-2007143422-A2 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | WO | claimed |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | claimed |
| EP-3492451-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3492451-A2 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| EP-3216784-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3216784-A1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2429996-B1 | PROCESS FOR THE PREPARATION OF HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-08 | — | — | EP | disclosed |
| US-9321729-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-26 | — | — | US | disclosed |
| US-7777031-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| US-7777031-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| US-7777031-B2 | Substituted pyridyl amide compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-17 | — | — | US | disclosed |
| WO-2007143422-A2 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087635-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1527/4885SLC6A2 752/4885 |
| US-20100267701-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1527/4885SLC6A2 752/4885 |
| US-20070281923-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 1527/4885SLC6A2 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.